Charles River Laboratories International Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.86B | $1.68B | $1.36B | $1.30B | $1.17B | $1.13B | $1.14B | $1.13B |
| Cost of Revenue | $289.7M | $277.0M | $264.0M | $266.4M | $272.8M | $257.7M | $268.0M | $253.0M |
| Gross Profit | $1.57B | $1.40B | $1.10B | $1.03B | $892.8M | $871.8M | $874.7M | $880.5M |
| Gross Margin | 84.4% | 83.5% | 80.6% | 79.5% | 76.6% | 77.2% | 76.5% | 77.7% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $371.3M | $364.7M | $300.4M | $269.0M | $225.7M | $208.2M | $198.6M | $232.5M |
| Operating Income | $288.3M | $237.6M | $206.4M | $177.7M | $151.4M | $165.8M | $174.3M | $-298.5M |
| Operating Margin | 15.5% | 14.1% | 15.1% | 13.7% | 13.0% | 14.7% | 15.3% | -26.3% |
| Interest Expense | $29.8M | $27.7M | $15.1M | $12.0M | $21.0M | $33.3M | $42.6M | $35.3M |
| Pretax Income | $297.0M | $222.9M | $195.4M | $177.6M | $138.3M | $129.7M | $132.7M | $-334.1M |
| Income Tax Expense | $171.4M | $66.8M | $43.4M | $47.7M | $32.9M | $27.6M | $17.1M | $23.0K |
| Net Income | $123.4M | $154.8M | $149.3M | $126.7M | $102.8M | $97.9M | $110.0M | $-336.7M |
| Net Margin | 6.6% | 9.2% | 11.0% | 9.8% | 8.8% | 8.7% | 9.6% | -29.7% |
| EPS (Basic) | $2.60 | $3.29 | $3.21 | $2.72 | $2.15 | $2.03 | $2.16 | $-5.38 |
| EPS (Diluted) | $2.54 | $3.23 | $3.13 | $2.66 | $2.12 | $2.01 | $2.14 | $-5.38 |
| Shares Outstanding (Basic) | 47.5M | 47.0M | 46.5M | 46.6M | 47.7M | 47.9M | 50.8M | 62.6M |
| Shares Outstanding (Diluted) | 48.6M | 48.0M | 47.6M | 47.6M | 48.5M | 48.4M | 51.3M | 62.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |